Virus-Immunotherapy cocktail takes on tough GI cancers

NCT ID NCT07280377

Ongoing Disease control Sponsor: Oncolytics Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a combination of pelareorep (a reovirus) and atezolizumab (an immunotherapy) along with standard chemotherapies in people with advanced anal or pancreatic cancers. The study aims to find safe doses, look for biomarkers that predict response, and measure early signs of tumor shrinkage or disease control. About 122 participants are enrolled across five groups, each receiving different drug combinations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pelareorep and atezolizumab (plus chemotherapy drugs like gemcitabine, nab-paclitaxel, trifluridine/tipiracil, or mFOLFIRINOX)
What this could lead to: If successful, this could point toward new treatment options for advanced gastrointestinal cancers that are hard to treat.
What could go wrong: This is an early phase 1/2 study with a small number of participants, so results may not confirm effectiveness. The combination therapies also carry risks of side effects from both the drugs and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anal squamous cell carcinoma exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL CANCER METASTATIC PANCREATIC CANCER METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANUS STAGE UNSPECIFIED UNRESECTABLE PANCREATIC CARCINOMA

Contacts and locations

Locations

Asklepios Kliniken Hamburg GmbH

Hamburg, Free and Hanseatic City of Hamburg, 22763, Germany
Caritasklinikum Saarbrücken St. Theresia

Saarbrücken, Saarland, 66113, Germany
Charité Universitätsklinikum Berlin

Berlin, State of Berlin, 13353, Germany
Gemeinschaftspraxis Dr. Med Bernhard Heinreich

Augsburg, Bavaria, 86150, Germany
Hämatologisch-Onkologische Praxis Eppendorf

Hamburg, Free and Hanseatic City of Hamburg, 20249, Germany
Klinikum Chemnitz gGmbH

Chemnitz, Saxony, 09116, Germany
Klinikum der Universität München

München, Bavaria, 81377, Germany
Krankenhaus Nordwest

Frankfurt am Main, Hesse, 60488, Germany
Nationales Centrum für Tumorerkrankungen Heidelberg

Heidelberg, Baden-Wurttemberg, 69120, Germany
SLK-Kliniken Heilbronn GmbH

Heilbronn, Baden-Wurttemberg, 74078, Germany
St. Josef-Hospìtal, Bochum

Bochum, North Rhine-Westphalia, 44791, Germany
Universität Leipzig

Leipzig, Saxony, 04103, Germany
Universitätsklinikum Tübingen

Tübingen, Baden-Wurttemberg, 72076, Germany
Universitätsklinikum Ulm

Ulm, Baden-Wurttemberg, 89081, Germany
Universitätsmedizin Mainz

Mainz, Rhineland-Palatinate, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.